Skip to main content
Top
Published in: Orphanet Journal of Rare Diseases 1/2011

Open Access 01-12-2011 | Research

"MY PKU": increasing self-management in patients with phenylketonuria. A randomized controlled trial

Authors: Amber E ten Hoedt, Carla EM Hollak, Carolien CA Boelen, N Ada P van der Herberg-van de Wetering, Nienke M ter Horst, Cora F Jonkers, Frits A Wijburg, Annet M Bosch

Published in: Orphanet Journal of Rare Diseases | Issue 1/2011

Login to get access

Abstract

Background

Phenylketonuria (PKU) is an autosomal recessive disorder of phenylalanine metabolism. The inability to convert phenylalanine (Phe) into tyrosine causes Phe to accumulate in the body. Adherence to a protein restricted diet, resulting in reduced Phe levels, is essential to prevent cognitive decline. Frequent evaluation of plasma Phe levels and, if necessary, adjustment of the diet are the mainstay of treatment. We aimed to assess whether increased self-management of PKU patients and/or their parents is feasible and safe, by providing direct online access to blood Phe values without immediate professional guidance.

Methods

Thirty-eight patients aged ≥ 1 year participated in a 10 month randomized controlled trial. Patients were randomized into a study group (1) or a control group (2). Group 2 continued the usual procedure: a phone call or e-mail by a dietician in case of a deviant Phe value. Group 1 was given a personal "My PKU" web page with a graph of their recent and previous Phe values, online general information about the dietary treatment and the Dutch PKU follow-up guidelines, and a message-box to contact their dietician if necessary. Phe values were provided on "My PKU" without advice. Outcome measures were: differences in mean Phe value, percentage of values above the recommended range and Phe sample frequency, between a 10-month pre-study period and the study period in each group, and between the groups in both periods. Furthermore we assessed satisfaction of patients and/or parents with the 'My PKU' procedure of online availability.

Results

There were no significant differences in mean Phe value, percentage of values above recommended range or in frequency of blood spot sampling for Phe determination between the pre-study period and the study period in each group, nor between the 2 groups during the periods. All patients and/or parents expressed a high level of satisfaction with the new way of disease management.

Conclusions

Increased self-management in PKU by providing patients and/or parents their Phe values without advice is feasible and safe and is highly appreciated.

Trial registration

The trial was registered with The Netherlands National Trial Register (NTR #1171) before recruitment of patients.
Appendix
Available only for authorised users
Literature
2.
go back to reference Waisbren SE, Noel K, Fahrbach K, Cella C, Frame D, Dorenbaum A, Levy H: Phenylalanine blood levels and clinical outcomes in phenylketonuria: a systematic literature review and meta-analysis. Mol Genet Metab. 2007, 92: 63-70. 10.1016/j.ymgme.2007.05.006.CrossRefPubMed Waisbren SE, Noel K, Fahrbach K, Cella C, Frame D, Dorenbaum A, Levy H: Phenylalanine blood levels and clinical outcomes in phenylketonuria: a systematic literature review and meta-analysis. Mol Genet Metab. 2007, 92: 63-70. 10.1016/j.ymgme.2007.05.006.CrossRefPubMed
3.
go back to reference Huijbregts SC, de Sonneville LM, Licht R, van Spronsen FJ, Verkerk PH, Sergeant JA: Sustained attention and inhibition of cognitive interference in treated phenylketonuria: associations with concurrent and lifetime phenylalanine concentrations. Neuropsychologia. 2002, 40: 7-15. 10.1016/S0028-3932(01)00078-1.CrossRefPubMed Huijbregts SC, de Sonneville LM, Licht R, van Spronsen FJ, Verkerk PH, Sergeant JA: Sustained attention and inhibition of cognitive interference in treated phenylketonuria: associations with concurrent and lifetime phenylalanine concentrations. Neuropsychologia. 2002, 40: 7-15. 10.1016/S0028-3932(01)00078-1.CrossRefPubMed
4.
go back to reference Report of Medical Research Council Working Party on Pheylketonuria: Recommendations on the dietary management of phenylketonuria. Arch Dis Child. 1993, 68: 426-427.CrossRef Report of Medical Research Council Working Party on Pheylketonuria: Recommendations on the dietary management of phenylketonuria. Arch Dis Child. 1993, 68: 426-427.CrossRef
5.
go back to reference National Institutes of Health Consensus Development Conference Statement: Phenylketonuria: Screening and Management. Pediatrics. 2001, 108: 972-982.CrossRef National Institutes of Health Consensus Development Conference Statement: Phenylketonuria: Screening and Management. Pediatrics. 2001, 108: 972-982.CrossRef
6.
go back to reference Blau N, Bélanger-Quintana A, Demirkol M, Feillet F, Giovannini M, MacDonald A, Trefz FK, van Spronsen F, European PKU centers: Management of phenylketonuria in Europe: survey results from 19 countries. Mol Genet Metab. 2010, 99: 109-115. 10.1016/j.ymgme.2009.09.005.CrossRefPubMed Blau N, Bélanger-Quintana A, Demirkol M, Feillet F, Giovannini M, MacDonald A, Trefz FK, van Spronsen F, European PKU centers: Management of phenylketonuria in Europe: survey results from 19 countries. Mol Genet Metab. 2010, 99: 109-115. 10.1016/j.ymgme.2009.09.005.CrossRefPubMed
7.
go back to reference Schweitzer-Krantz S, Burgard P: Survey of national guidelines for the treatment of phenylketonuria. Eur J Pediatr. 2000, 159: S70-73. 10.1007/PL00014385.CrossRefPubMed Schweitzer-Krantz S, Burgard P: Survey of national guidelines for the treatment of phenylketonuria. Eur J Pediatr. 2000, 159: S70-73. 10.1007/PL00014385.CrossRefPubMed
8.
go back to reference Macdonald A, Gokmen-Ozel H, van Rijn M, Burgard P: The reality of dietary compliance in the management of phenylketonuria. J Inherit Metab Dis. 2010. Macdonald A, Gokmen-Ozel H, van Rijn M, Burgard P: The reality of dietary compliance in the management of phenylketonuria. J Inherit Metab Dis. 2010.
9.
go back to reference McAndrew L, Schneider SH, Burns E, Leventhal H: Does patient blood glucose monitoring improve diabetes control? A systematic review of the literature. Diabetes Educ. 2007, 33: 991-1011. 10.1177/0145721707309807.CrossRefPubMed McAndrew L, Schneider SH, Burns E, Leventhal H: Does patient blood glucose monitoring improve diabetes control? A systematic review of the literature. Diabetes Educ. 2007, 33: 991-1011. 10.1177/0145721707309807.CrossRefPubMed
10.
11.
go back to reference Bray EP, Holder R, Mant J, McManus RJ: Does self-monitoring reduce blood pressure? Meta-analysis with meta-regression of randomized controlled trials. Ann Med. 2010, 42: 371-386. 10.3109/07853890.2010.489567.CrossRefPubMed Bray EP, Holder R, Mant J, McManus RJ: Does self-monitoring reduce blood pressure? Meta-analysis with meta-regression of randomized controlled trials. Ann Med. 2010, 42: 371-386. 10.3109/07853890.2010.489567.CrossRefPubMed
12.
go back to reference Siebenhofer A, Berghold A, Sawicki PT: Systematic review of studies of self-management of oral anticoagulation. Thromb Haemost. 2004, 91: 225-232.PubMed Siebenhofer A, Berghold A, Sawicki PT: Systematic review of studies of self-management of oral anticoagulation. Thromb Haemost. 2004, 91: 225-232.PubMed
13.
go back to reference Bekhof J, van Rijn M, Sauer PJ, Ten Vergert EM, Reijngoud DJ, van Spronsen FJ: Plasma phenylalanine in patients with phenylketonuria self-managing their diet. Arch Dis Child. 2005, 90: 163-164. 10.1136/adc.2003.040451.PubMedCentralCrossRefPubMed Bekhof J, van Rijn M, Sauer PJ, Ten Vergert EM, Reijngoud DJ, van Spronsen FJ: Plasma phenylalanine in patients with phenylketonuria self-managing their diet. Arch Dis Child. 2005, 90: 163-164. 10.1136/adc.2003.040451.PubMedCentralCrossRefPubMed
14.
go back to reference Wendel U, Langenbeck U: Towards self-monitoring and self-treatment in phenylketonuria-a way to better diet compliance. Eur J Pediatr. 1996, 155 (S1): 105-107. 10.1007/PL00014224.CrossRef Wendel U, Langenbeck U: Towards self-monitoring and self-treatment in phenylketonuria-a way to better diet compliance. Eur J Pediatr. 1996, 155 (S1): 105-107. 10.1007/PL00014224.CrossRef
15.
go back to reference Scriver CR, Kaufman S, Eisensmith E, Woo SLC: The hyperphenylalaninemias. The Metabolic and Molecular Bases of Inherited Disease. 7 edition. Edited by: Scriver CR, Beaudet AL, Sly WS, Valle D. New York: McGraw-Hill; 1995: 1015-1075. Scriver CR, Kaufman S, Eisensmith E, Woo SLC: The hyperphenylalaninemias. The Metabolic and Molecular Bases of Inherited Disease. 7 edition. Edited by: Scriver CR, Beaudet AL, Sly WS, Valle D. New York: McGraw-Hill; 1995: 1015-1075.
16.
go back to reference Kayaalp E, Treacy E, Waters PJ, Byck S, Nowacki P, Scriver CR: Human phenylalanine hydroxylase mutations and hyperphenylalaninemia phenotypes: a metanalysis of genotype-phenotype correlations. Am J Hum Genet. 1997, 61: 1309-1317. 10.1086/301638.PubMedCentralCrossRefPubMed Kayaalp E, Treacy E, Waters PJ, Byck S, Nowacki P, Scriver CR: Human phenylalanine hydroxylase mutations and hyperphenylalaninemia phenotypes: a metanalysis of genotype-phenotype correlations. Am J Hum Genet. 1997, 61: 1309-1317. 10.1086/301638.PubMedCentralCrossRefPubMed
17.
go back to reference Blau N, van Spronsen FJ, Levy HL: Phenylketonuria. Lancet. 2010, 376: 1417-1427. 10.1016/S0140-6736(10)60961-0.CrossRefPubMed Blau N, van Spronsen FJ, Levy HL: Phenylketonuria. Lancet. 2010, 376: 1417-1427. 10.1016/S0140-6736(10)60961-0.CrossRefPubMed
18.
go back to reference Pocock SJ, Simon R: Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics. 1975, 31: 103-115.CrossRefPubMed Pocock SJ, Simon R: Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics. 1975, 31: 103-115.CrossRefPubMed
19.
go back to reference Walter JH, White FJ, Hall SK, MacDonald A, Rylance G, Boneh A, Francis DE, Shortland GJ, Schmidt M, Vail A: How practical are recommendations for dietary control in phenylketonuria?. Lancet. 2002, 360: 55-57. 10.1016/S0140-6736(02)09334-0.CrossRefPubMed Walter JH, White FJ, Hall SK, MacDonald A, Rylance G, Boneh A, Francis DE, Shortland GJ, Schmidt M, Vail A: How practical are recommendations for dietary control in phenylketonuria?. Lancet. 2002, 360: 55-57. 10.1016/S0140-6736(02)09334-0.CrossRefPubMed
20.
go back to reference Burgard P, Schmidt E, Rupp A, Schneider W, Bremer HJ: Intellectual development of the patients of the German Collaborative Study of children treated for phenylketonuria. Eur J Pediatr. 1996, 155 (S1): S33-38. 10.1007/PL00014245.CrossRefPubMed Burgard P, Schmidt E, Rupp A, Schneider W, Bremer HJ: Intellectual development of the patients of the German Collaborative Study of children treated for phenylketonuria. Eur J Pediatr. 1996, 155 (S1): S33-38. 10.1007/PL00014245.CrossRefPubMed
21.
go back to reference Cochran J, Conn VS: Meta-analysis of quality of life outcomes following diabetes self-management training. Diabetes Educ. 2008, 34: 815-823. 10.1177/0145721708323640.PubMedCentralCrossRefPubMed Cochran J, Conn VS: Meta-analysis of quality of life outcomes following diabetes self-management training. Diabetes Educ. 2008, 34: 815-823. 10.1177/0145721708323640.PubMedCentralCrossRefPubMed
22.
go back to reference Pibernik-Okanovic M, Prasek M, Poljicanin-Filipovic T, Pavlic-Renar I, Metelko Z: Effects of an empowerment-based psychosocial intervention on quality of life and metabolic control in type 2 diabetic patients. Patient Educ Couns. 2004, 52: 193-199. 10.1016/S0738-3991(03)00038-7.CrossRefPubMed Pibernik-Okanovic M, Prasek M, Poljicanin-Filipovic T, Pavlic-Renar I, Metelko Z: Effects of an empowerment-based psychosocial intervention on quality of life and metabolic control in type 2 diabetic patients. Patient Educ Couns. 2004, 52: 193-199. 10.1016/S0738-3991(03)00038-7.CrossRefPubMed
23.
go back to reference McCahon D, Murray ET, Murray K, Holder RL, Fitzmaurice DA: Does self-management of oral anticoagulation therapy improve quality of life and anxiety?. Fam Pract. 2010, 10. McCahon D, Murray ET, Murray K, Holder RL, Fitzmaurice DA: Does self-management of oral anticoagulation therapy improve quality of life and anxiety?. Fam Pract. 2010, 10.
24.
go back to reference Kuijer RG, De Ridder DTD: Discrepancy in Illness-related Goals and Quality of Life in Chronically Ill Patients: The Role of Self-efficacy. Psychol & Health. 2003, 18: 313-330.CrossRef Kuijer RG, De Ridder DTD: Discrepancy in Illness-related Goals and Quality of Life in Chronically Ill Patients: The Role of Self-efficacy. Psychol & Health. 2003, 18: 313-330.CrossRef
Metadata
Title
"MY PKU": increasing self-management in patients with phenylketonuria. A randomized controlled trial
Authors
Amber E ten Hoedt
Carla EM Hollak
Carolien CA Boelen
N Ada P van der Herberg-van de Wetering
Nienke M ter Horst
Cora F Jonkers
Frits A Wijburg
Annet M Bosch
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Orphanet Journal of Rare Diseases / Issue 1/2011
Electronic ISSN: 1750-1172
DOI
https://doi.org/10.1186/1750-1172-6-48

Other articles of this Issue 1/2011

Orphanet Journal of Rare Diseases 1/2011 Go to the issue